Robertson Stephens Wealth Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Robertson Stephens Wealth Management’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-135	Closed	-$167K	–	409
2022 Q1	$167K	Sell	135 -71	-34%	-$96.6K	0.01%	375
2021 Q4	$519K	Buy	206 +107	+108%	+$653K	0.04%	252
2021 Q3	$1.81M	Sell	99 -41	-29%	-$652K	0.2%	77
2021 Q2	$1.48M	Buy	140 +21	+18%	+$176K	0.18%	92
2021 Q1	$859K	Buy	119 +55	+86%	+$396K	0.14%	116
2020 Q4	$353K	Buy	+64	New	+$567K	0.07%	170

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Robertson Stephens Wealth Management's IRLA Position: Q2 2022 in Review

Robertson Stephens Wealth Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 135 shares — an estimated $167K sold.

Robertson Stephens Wealth Management first reported a position in IRLA in Q4 2020 and held it in 6 quarters. The position peaked at $1.81M in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

Robertson Stephens Wealth Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Robertson Stephens Wealth Management sold 135 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $167K.
Robertson Stephens Wealth Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Robertson Stephens Wealth Management's IRulya Therapeutics Inc. Common Stock position peaked at $1.81M in Q3 2021.
66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Robertson Stephens Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.